DS
Therapeutic Areas
Bicara Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| BCA101 | Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) | Phase 1b/2 |
Leadership Team at Bicara Therapeutics
CM
Claire Mazur
Chief Executive Officer
F(
Fortunato (Fred) C. O. (Chuck) Olson
Chief Scientific Officer
DJ
David J. Donabedian
Chief Technology Officer
MJ
Mark J. Charette
Chief Business Officer
J(
James (Jim) P. Boylan
Chief Financial Officer